Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Apply
REGN4018 & Cemiplimab
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step